AmpliPhi Biosciences (APHB) Misses Q2 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to AmpliPhi Biosciences (APHB) Misses Q2 EPS by 12c

AmpliPhi Biosciences Reports Second Quarter 2016 Financial Results and Provides Corporate Update

August 15, 2016 4:10 PM EDT

SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the second quarter ended June 30, 2016.

We have made significant progress executing on our clinical programs and look forward to presenting top-line data for both clinical trials later this year, said M. Scott Salka, CEO of AmpliPhi Biosciences. The threat posed by drug-resistant infections is universally acknowledged. World leaders from government, medical and scientific communities continue to stress the importance of addressing this threat, and we remain... More